Biopharmaceutical News and Research

RSS

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Investment report on Idenix Pharmaceuticals

StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Investment report on Anadys Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Anadys Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Apr 2010

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus.

16 Apr 2010

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Emisphere Technologies, Inc. today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen Technology.

16 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Investment report on MIPI

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions, has signed a global SaaS CRM agreement with biopharmaceutical company UCB.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research 101st Annual Meeting 2010 being held April 17-21, 2010, in Washington, D.C.

13 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.

13 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) for its 2010 Annual Meeting of Stockholders. The Company has nominated Robert Forrester, a highly qualified independent director candidate, for election to the Board of Directors at the meeting.

12 Apr 2010

CoreLab Partners' new logo and brand identity launched

CoreLab Partners, Inc, the recently established global entity resulting from the merger between RadPharm and Medifacts International, has launched a new brand identity to reinforce their capabilities as one of the largest imaging sciences and cardiac safety core labs in the market today.

12 Apr 2010

BioClinica to showcase expanded suite of services at upcoming global industry conferences

BioClinica, Inc., a leading provider of clinical trial management services will participate in, and present at, key industry conferences during April and May. Principal members of the BioClinica team will participate as expert panelists as well as demonstrate the value of the Company's expanded suite of services at these conferences.

From Clario 12 Apr 2010

Biopharmaceutical News and Research

RegeneRx Biopharmaceuticals proposes common stock public offering

Investment report on Idenix Pharmaceuticals

Investment report on Anadys Pharmaceuticals

Promising pharmacokinetic data from Idenix Pharmaceuticals' Phase I study of IDX320 for HCV

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Investment report on MIPI

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

Cegedim Dendrite announces global SaaS CRM agreement with UCB

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

AVEO Pharmaceuticals to present preclinical data from translational research platform at AACR 2010

Investment report on Rexahn Pharmaceuticals

NeoStem opens new adult stem cell collection center in Austin, TX

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CoreLab Partners' new logo and brand identity launched

BioClinica to showcase expanded suite of services at upcoming global industry conferences

Industry Focus - Biopharma eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News